NICE and Cochrane have signed a collaborative agreement which will help to deliver ‘living’ recommendations across the NICE guideline portfolio.
The agreement will mean that the NHS and patients will benefit from a collaborative process which will enable NICE to better use Cochrane reviews in responding to changes in the evidence. The partnership will allow NICE to make efficient and effective updates to the recommendations in its guidelines.
The announcement follows the recent publication of NICE’s new 5-year strategy which commits it to finding more flexible and faster ways of working. One of the key aims to the strategy is to provide dynamic, living guideline recommendations that are useful, useable and rapidly updated.
Cochrane has a long-established relationship with the NHS and receives a large proportion of its funding from the National Institute for Health Research (NIHR), and their systematic reviews of health evidence are already used to inform NICE guidelines.
During NICE’s 2021 update of its guideline on ectopic pregnancy and miscarriage, Cochrane’s network meta-analysis of progestogens for preventing miscarriage was presented to the independent guideline committee. This allowed the committee to make recommendations more efficiently due to early access to all the latest evidence.
Click here to read the original press release.
